Transarterial Chemoembolization (TACE)

Treatment for Liver cancer due to hepatitis C

Effectiveness
70%
Safety Score
60%
Clinical Trials
100
Participants
30K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Time to Effect
1-2 months
Treatment Duration
Multiple sessions (1-3+ per year), ongoing surveillance
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$7,500
Side Effect Mgmt:$2,000
Total Annual:$9,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$80,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$15,833
Comparison vs Best Supportive Care
Cost Difference
+$20,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Transarterial Chemoembolization (TACE) Outcomes

for Liver cancer due to hepatitis C

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+60%
Common Side Effects
Post-embolization syndrome (fever, pain, nausea)
+70%
Liver dysfunction
+10%
Biloma/abscess
+2%

Sources:

nih.gov
mdpi.com
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov